<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-18T22:38:30.432Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-18T22:38:30.432Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-18T22:38:30.432Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-18T22:38:30.432Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-18T22:38:30.432Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/PCYO:1795041132000</loc>
    <lastmod>2026-11-18T22:32:12.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/PCYO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Pure Cycle Corporation Announces Record Financial Results for Fiscal Year 2026</image:title>
      <image:caption>Pure Cycle Corporation reported record fiscal 2026 revenue of $35.7 million for the year ended August 31, up 37% from the prior fiscal year. Revenue increased across all three business segments, with lot sales revenue rising 45%, driven by accelerated development at the Sky Ranch project. The company operates as a water and wastewater service provider and land developer.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MAGN:1795041120000</loc>
    <lastmod>2026-11-18T22:32:00.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MAGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Magnera Reports Fourth Quarter and Fiscal Year 2026 Results</image:title>
      <image:caption>Magnera Corporation reported fourth-quarter fiscal 2026 net sales of $851 million and an operating loss of $90 million. The loss included $106 million in charges related to goodwill and other items. The company released the results on November 18, 2026.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/UTI:1795041101000</loc>
    <lastmod>2026-11-18T22:31:41.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/UTI/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Universal Technical Institute, Inc. Reports Fiscal 2026 Fourth Quarter and Full Year Financial Results</image:title>
      <image:caption>Universal Technical Institute reported fiscal 2026 revenue of $897.0 million, up 7.4% year over year, and net income of $33.6 million. Fourth-quarter revenue rose 6.0% to $235.9 million, while adjusted EBITDA increased 15.5% to $42.5 million; quarterly basic and diluted EPS were $0.33 and $0.32. The company cited growth in its UTI and Concorde segments and spent $112.9 million on capital projects, including new campuses, programs, and facility upgrades. For fiscal 2027, it forecast revenue of $925 million to $945 million and EPS of $0.00 to $0.09.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NFLX:1795041100000</loc>
    <lastmod>2026-11-18T22:31:40.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NFLX/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Netflix Lowers 2026 Advertising Revenue Target and Provides Soft Q4 Guidance</image:title>
      <image:caption>Netflix lowered its 2026 advertising revenue target to $2.7 billion from $3 billion, citing a slower-than-expected rollout of its advertising capabilities. It forecast Q4 2026 revenue of $13.4 billion, below analyst consensus. Revenue growth slowed from 17.6% in Q4 2025 to 11.8% in Q3 2026, and the revised outlook has heightened investor concerns about engagement and the company’s ability to scale newer monetization initiatives.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/PANW:1795037549000</loc>
    <lastmod>2026-11-18T21:32:29.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/PANW/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Palo Alto Networks Reports Q1 Fiscal 2027 Earnings and Announces Acquisition of Applied Compute</image:title>
      <image:caption>Palo Alto Networks reported fiscal Q1 2027 adjusted EPS of $1.05 and agreed to acquire AI startup Applied Compute for $4.5 billion. The company raised its fiscal 2027 revenue outlook to $14.52 billion–$14.57 billion, above the FactSet consensus of $14.17 billion. For Q2, it forecast revenue of $3.53 billion–$3.55 billion and adjusted EPS of $1.01–$1.03.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/LLY:1795037489000</loc>
    <lastmod>2026-11-18T21:31:29.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Health Canada Approves Mounjaro for Cardiovascular Risk Reduction</image:title>
      <image:caption>Health Canada granted Eli Lilly Canada a Notice of Compliance for Mounjaro (tirzepatide) to reduce major adverse cardiovascular events—including cardiovascular death, non-fatal heart attack, and non-fatal stroke—in adults with type 2 diabetes and established cardiovascular disease. The approval is based on clinical data showing improved cardiovascular outcomes in this population. Lilly said the drug’s safety profile was consistent with its established profile, with gastrointestinal events most common; the article reported no financial figures or stock-price impact.</image:caption>
    </image:image>
  </url>
</urlset>